ERCC5 and cancer: Of note, HPV-negative HNSCC with NSD1 mutations were associated with a decreased expression of ERCC5 mRNA levels [59], and inactivation of ERCC5 has been previously shown to increase sensitivity to cisplatin in a variety of cancers [60,61].